Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Blood test gives early warning of skin cancer relapse

14 March 2016

By Dr Lucy Freem

Appeared in BioNews 843

Scientists have developed a blood test that captures tumour DNA from stray cancer cells circulating in the blood and allows them to monitor genetic changes in skin cancer.

These changes can give an early warning of the cancer becoming resistant to treatment, which can result in a dormant cancer re-emerging.

'Being able to spot the first signs of relapse, so we can rapidly decide the best treatment strategy, is an important area for research,' said lead study author Professor Richard Marais. 'Using our technique we hope that one day we will be able to spot when a patient's disease is coming back at the earliest point and start treatment against this much sooner.'

The study at the Cancer Research UK Manchester Institute examined 364 blood and tumour samples from 214 patients to develop a non-invasive way to track genetic changes in skin cancer cells, using DNA from blood samples.

They showed that the test picked up the emergence of drug-resistant cancer cells and the subsequent re-emergence of cancer before standard clinical examinations. Tracking these changes could allow doctors to tailor treatment to individual skin cancer cases, and the faster the changes are detected the more quickly treatments can be altered to keep skin cancer under control.

Malignant melanoma is an aggressive type of skin cancer and is the fifth most common cancer in Britain. Around 15,000 people are diagnosed every year in the UK, and once the cancer progresses to malignancy it is often fatal.

The progression of the disease varies from patient to patient, depending on which genetic changes are present in cancer cells. Around half of melanoma patients have cancer cells with a genetic change in the BRAF gene, which means they can be treated with recently developed targeted drugs like vemurafenib. However, some patients' tumours develop resistance to these drugs after a relatively short time. When this happens, these patients can be offered different immunotherapy drugs that the cancer is still susceptible to.

Researchers said that detecting this resistance early could be key to improving patient care and survival.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: 'One of the sinister things about melanoma is that it can lay dormant for years and then suddenly re-emerge, probably as it escapes from the control of the body's immune system. Being able to track cancers in real time as they evolve following treatment has huge potential for the way we monitor cancers and intervene to stop them growing back.

'There's still some time until we see this in the clinic but we hope that in the future, blood tests like these will help us to stay one step ahead in treating cancer.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

12 September 2016 - by Meetal Solanki 
A blood test costing only £35 could help in the early diagnosis of oesophageal cancer and could be available in five years' time...
11 April 2016 - by Rikita Patel 
The gene responsible for red hair raises the risk of melanoma whether or not people spend a long time in the sun, a study says...
21 March 2016 - by Hannah Somers 
Scientists say they have been able to detect multiple diseases, including pancreatic cancer, multiple sclerosis and type 1 diabetes, by analysing fragments of DNA in the bloodstream...

08 February 2016 - by Helen Robertson 
Researchers have visualised the onset of skin cancer at its earliest, single-cell stage for the first time...
09 November 2015 - by Kirsty Oswald 
Researchers have identified the genetic mutations that drive resistance to the hormone therapy abiraterone in patients with advanced prostate cancer...
09 November 2015 - by Ayala Ochert 
Scientists say it may be possible to track the progress of cancer – and cancer treatment – in real time from fragments of tumour DNA that are shed into the bloodstream...
14 September 2015 - by Isobel Steer 
A US startup called Pathway Genomics has launched the first commercial 'liquid biopsy' to identify cancerous mutations via a blood test...
14 April 2014 - by Simon Hazelwood-Smith 
A genetic test has been developed to predict the likelihood of prostate cancer returning after treatment. The test looks for 'genetic signatures' often found in recurring cancers...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation